chartexchange

Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

GlobeNewswire Inc. | Nov 9, 2026 4:05 PM EST

Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027

Read original article